• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Silo Pharma, Inc. - Common Stock (NQ:SILO)

    6.145 -0.035 (-0.57%)
    Streaming Delayed Price Updated: 10:03 AM EDT, Jul 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Silo Pharma, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    News headline image
    Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models ↗
    Silo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and fibromyalgia. 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
     
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Alzheimer’s Drug SPC-14
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
    Via Investor Brand Network
    News headline image
    Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
    From Silo Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Secures USPTO Patent for PTSD Treatment SPC-15
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Provisional Patent for SPC-15 Dual-Action Treatment
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Early Data on SP-26 Ketamine Implant Study
    Via Investor Brand Network
    Topics Animal Testing
    News headline image
    Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
    From Silo Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Bolsters Intellectual Property with New Patent Filing for PTSD Treatment
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Silo Pharma Shares Are Surging Today: What's Going On? ↗
    Silo Pharma Inc.'s stock (NASDAQ: SILO) is on the the rise Wednesday following the company's announcement that it has been awarded a U.S. patent for its PTSD treatment titled "Pharmacological... 
    Via Benzinga
    Topics Intellectual Property
    News headline image
    Crude Oil Down 1%; US Weekly Jobless Claims Decline ↗
     
    Via Benzinga
    News headline image
    US Stocks Down; Acuity Brands Posts Weak Revenue ↗
     
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Strengthens Patent Portfolio with Approval for PTSD Treatment SPC-15
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Ketamine Implant Development with Pharmacokinetic Study
    Via Investor Brand Network
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partners with Kymanox to Advance Ketamine Implant Therapeutic for Chronic Pain
    Via Investor Brand Network
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Why Is Silo Pharma Stock Gaining Today? ↗
    Silo Pharma stock is rising after announcing a collaboration with Kymanox to develop a subcutaneous insertion device for its SP-26 chronic pain treatment. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.